NCT04061109 - Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions

Hemophilia A

Interventions

DRUG

Recombinant Human Coagulation FVIII

A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.

Trial Locations (11)

210008

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

230001

RECRUITING

AnHui Provincial Hospital, Hefei

300020

RECRUITING

Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

330006

RECRUITING

Jiangxi Provincial People's Hospital, Nanchang

350001

RECRUITING

FuJian Medical University Union Hospital, Fuzhou

400010

RECRUITING

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410013

RECRUITING

Xiangya Hospital Central South University, Changsha

450003

RECRUITING

HeNan Provincial Peoples Hospital, Zhengzhou

450008

RECRUITING

HeNan Cancer Provincial Hospital, Zhengzhou

530021

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

730000

RECRUITING

The First Hospital of LanZhou University, Lanzhou